From the same PKI newswire: PerkinElmer tweaked its full-year forecast range and now expects to earn $2.00 to $2.05 per share excluding items. (It had previously forecast $1.98 to $2.04 per share.) …The Human Health division, which includes neonatal testing and other diagnostic equipment, saw sales jump 26 percent to $254.0 million [this includes the effect of the CALP acquisition]. PKI also reported >20% organic growth (i.e. excluding the CALP acquisition) in the BRIC countries (http://seekingalpha.com/article/534591-perkinelmer-s-ceo-discusses-q1-2012-results-earnings-call-transcript ).